<DOC>
	<DOCNO>NCT01279083</DOCNO>
	<brief_summary>To investigate safety efficacy DE-112 lower intraocular pressure subject primary open-angle glaucoma ocular hypertension .</brief_summary>
	<brief_title>Safety Efficacy Trial Treat Open-Angle Glaucoma Ocular Hypertension</brief_title>
	<detailed_description>This study conduct two stage . Stage One open-label , adaptive dose-selection , safety efficacy trial four concentration DE-112 ophthalmic solution enrol total 24 subject . Stage Two study randomize , double-masked , placebo- active-controlled , parallel-group , multi-center trial compare efficacy safety two concentration DE-112 ophthalmic solution placebo timolol enrol total 120 subject .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Maleic acid</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Provide sign , write informed consent 18 yeas age old Diagnosed primary openangle glaucoma ocular hypertension Female subject childbearing potential must utilize reliable contraceptive throughout study negative urine pregnancy test prior enrollment study Meet specific Visit 2 , Day 0 ( Baseline ) criteria baseline Females pregnant , nurse plan pregnancy Presence abnormality significant illness could expect interfere study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>